Investor Relations
Medgen Life Science is positioned at the intersection of China's growing demand for regenerative repair materials and the national push for import substitution in medical devices.
Market Opportunity
Multiple converging trends are creating substantial growth opportunities in China's regenerative repair materials market.
China's bone repair materials market is growing rapidly, driven by an aging population, increasing prevalence of orthopedic conditions, and rising surgical volumes. The market remains significantly under-penetrated compared to developed countries.
China's dental implant market is experiencing rapid expansion following government-led volume-based procurement reforms that have made implant procedures more accessible. Bone grafting is required in a significant proportion of implant cases, driving demand for materials like PoroGraft®.
National policies strongly encourage adoption of domestically developed medical devices. Hospital procurement increasingly favors domestic products that meet equivalent quality standards, creating a structural advantage for companies like Medgen with NMPA-approved products.
Funding History
Medgen has secured institutional financing to fund product development, regulatory approvals, and commercial launch activities.
Tens of Millions RMB
Raised to accelerate regulatory submissions for BoneSwift™ and PoroGraft®, expand the team, and build commercial infrastructure for product launches in 2025.
Follow-On Round
Closed shortly after the Series A to strengthen the balance sheet ahead of dual product approvals and support nationwide commercial rollout and market development activities.
Product Pipeline
A diversified portfolio of regenerative repair products spanning approved products and development-stage candidates.
BoneSwift™
ApprovedInjectable Bone Repair Material
China’s first pre-filled injectable bone repair material. NMPA Class III approved (March 2025). Ready-to-use delivery system for bone void filling in orthopedic procedures.
PoroGraft®
ApprovedXenograft Bone Graft
China’s first porcine-derived oral bone graft material. NMPA Class III approved (April 2025). Controlled porosity architecture for guided bone regeneration in dental implant procedures.
PRP System
In DevelopmentPlatelet-Rich Plasma
Autologous platelet-rich plasma preparation system for point-of-care use. Designed to complement our bone repair portfolio with growth factor delivery for enhanced healing.
Next-Generation Biomaterials
ResearchFuture Pipeline
Expanding our regenerative materials platform into additional clinical applications, leveraging our core competencies in natural-derived biomaterial processing and controlled porosity engineering.
Competitive Advantages
Medgen's competitive position is underpinned by a combination of technology differentiation, regulatory milestones, and market timing.
BoneSwift™ is the first pre-filled injectable bone repair material approved in China, establishing a new product category with significant barriers to entry for competitors.
Proprietary processing of natural bone tissue preserves native collagen and mineral structure, delivering superior osteoconductive performance versus synthetic alternatives.
Co-founded with the support of Prof. Cato Laurencin’s regenerative engineering institute. Prof. Laurencin is elected to all three U.S. national academies (NAM, NAE, NAS).
Two NMPA Class III medical device approvals achieved within months of each other (March and April 2025), demonstrating strong regulatory execution capability.
Government policies actively encourage domestic medical device adoption. Medgen’s products offer comparable or superior performance to imported alternatives at competitive pricing.
Core technology platforms in biomaterial processing, porosity engineering, and delivery systems are extensible across multiple product categories and clinical applications.
Investor Inquiries
For investor relations inquiries, partnership discussions, or to request additional information about Medgen Life Science, please contact us.
info@medgenlife.com
Contact Us